CrystecPharma are pleased to announce the approval of patent applications for their lead asset, CR002. Applications with China’s National Intellectual Property Administration (CNIPA) and the European Patent Office (EPO) have recently been approved. National filings are ongoing in other key territories.
November 5, 2019
Crystec are honoured to have been awarded the Making Pharmaceuticals Award for Innovation in Manufacturing. The award was presented for Crystec’s mSAS® (modified Supercritical Anti-Solvent) technology and chosen from shortlisted companies including kg-pharma, iDi Pac, Glatt Protech and SSPC, Bernal Institute.
Crystec’s CEO, Paul Thorning, has contributed to an article by UBM featuring the big issues affecting Pharma for 2019, according to key opinion leaders in the industry. Contributors include representatives from PharmSource, Catalent Pharma Solutions and NIBRT.